=-=Vir Biotechnology (VIR) : failed seasonal influenza study

 

Vir Biotechnology announces topline data from phase 2 peninsula trial evaluating vir-2482 for the prevention of seasonal influenza 

• Co announced that the Phase 2 PENINSULA (PrevEntioN of IllNesS DUe to InfLuenza A) trial evaluating VIR-2482 for the prevention of symptomatic influenza A illness did not meet primary or secondary efficacy endpoints. In participants who received the highest dose of VIR-2482 (1,200 mg), a non-statistically significant reduction of approximately 16% in influenza A protocol-defined illness was observed. Participants who received the highest dose showed an approximately 57% reduction in symptomatic influenza A illness, when defined according to CDC influenza-like-illness criteria, which was one of two secondary endpoints. VIR-2482 was generally well tolerated and no safety signals were identified.
• PENINSULA (NCT05567783) is the first Phase 2 outpatient trial to evaluate the role of a monoclonal antibody in the prevention of influenza A illness. The dose-ranging, proof-of-concept trial enrolled approximately 3,000 men and women ages 18 to 64 without risk factors for serious complications from an influenza infection who did not receive an influenza vaccination for the flu season. The primary efficacy endpoint was the proportion of trial participants with protocol-defined influenza-like-illness1 with PCR-confirmed influenza A infection compared to placebo. Secondary endpoints included the proportion of participants with CDC-defined influenza-like-illness2 with PCR-confirmed influenza A infection and the proportion of participants with WHO-defined influenza-like-illness3 with PCR-confirmed influenza A infection.

===Vir Biotechnology (VIR) reported earnings on Thur 3 Nov 22 (a/h)

 

Vir Biotechnology reports Q3 (Sep) results, beats on revs 

• Reports Q3 (Sep) earnings of $1.30 per share, may not be comparable to the S&P Capital IQ Consensus of ($0.31); revenues rose 235.5% year/year to $347.6 mln vs the $114.28 mln S&P Capital IQ Consensus.
• Provision for income taxes for the quarter ended September 30, 2022, was $42.4 million, compared to a $0.3 million for the same period in 2021. The increase in for the quarter was primarily due to the Company's estimated taxable income for 2022 attributable to collaboration revenue recognized under the 2020 GSK agreement and the requirement under the Tax Cuts and Jobs Act of 2017 for taxpayers to capitalize and amortize research and development expenditures over five or fifteen years pursuant to Section 174 of the Internal Revenue Code of 1986, as amended.

Earnings this week : Oct 31 - Nov 4, 22 (wk 44)

Monday (Oct 31)

• Morning:  CNA GPN HWM NSP JELD ON PEG SAIA XPO
• Afternoon: ACHC ADUS AFL AWK AMKR ANET CAR AXNX NTB BCC CHE CINF CIVI CNO PLOW FLS GT HLIT HTLF HLF HOLX IMAX KMT KFRC LSCC LEG VAC NXPI OGS OTTR PSMT RMBS RRX RHP SBAC SON SYK TREX VRNS VNO WMB

Tuesday (Nov 1)

• Morning: ABMD AJRD AGCO AME ARCB ARNC AVA TECH BCOR BPMC BP CTLT CNP CIGI CVLT DEA ETN ECL ECVT LLY NPO EPD ETRN ESPR FOXA BEN IT HLNE HSC HAYW HSIC IDXX INCY ICPT IPGP KKR LCII LEA LDOS LGIH LPX MPC TAP MPLX MYGN NBIX NEM PFE PSX PBI PINC PACK RGEN SAFE STNG SEE SPG SIRI SOFI SUN SYY TRI BLD TRTN UBER WAB WAT WEC XYL ZBRA
• Afternoon:  AEIS AMD ABNB AYX AIG ANDE APAM AMK AIZ ATCO ATRC BTG BAND BLKB BFAM BRX CZR CWH CDLX CAKE CHGG CHK CRUS CLX CRK CNDT CACC DENN DVN EIX EA ET EXEL EXR FMC FCPT FRPT FRSH HRB THG PEAK HURN INSP INST IRTC JRVR KAI KAR LFUS LTHM MGY MTCH MCK MRCY MSTR MIR MDLZ NMIH OI OKE OSPN PAYC PUMP PRO PRU PSA RNR REZI SPNE SCI SIMO TSLX SKY SNCY SMCI UNVR UNM VRSK VRAY VOYA WU YUMC ZETA ZI

Wednesday (Nov 2)

• Morning:  ACIW ALKS ATI APO ASTE AVNS AVDX AVNT BDC EAT BR BIP CHRW GOOS CDW FUN CVE CRL CLH CVS DIN DFIN DT EDIT EMR ENOV ENTG ETR EL EXPI RACE FDP FYBR GNRC THRM HZNP HUM INGN JLL LIVN LL MLM MTRN MLCO NNN NYT DNOW ODP OMCL PARA PSN RDWR RITM ROK SABR SMG SBGI SITE SHC SHOO TEL TT TRMB TUP UTHR VSH VMC XHR YUM ZBH
• Afternoon:  TXG ACAD ALB ALGT ALL ATUS AFG AMPL ANSS APA ACA ACLS BKH BKNG BCOV CRC CPE CDAY CF CTSH CFLT CLR CXW CCRN CW ELF ESTE EBAY ECPG EPR EQIX EQH ETSY ES EVTC EVGO EVOP EVH FARO FSLY FSR FLT FTNT GFL GKOS HTGC HST TWNK HUBS HBM HPP ICLR NARI INFN IR NGVT IIPR FROG KMPR KW LHCG LSI LNC LUMN MBI  MRO MRVI MATX MET MTG MGM MKSI MC NRDS  NSA NVRO NE NUS NTR OHI ONL ORA PLMR PK PYCR PDCE PDM PAA POWI PCOR PTRA PTC QRVO QCOM QLYS QDEL RDN RPD RYN O RGNX RCII RVLV RLJ HOOD ROKU RPT RSI SRPT SIGI SITM STAA SRI RGR SUM SLF SU RUN TNDM SKT RIG TTMI TPC UDMY RARE VCYT VMEO VSTO HCC WCN WTS WERN WES WSC WK WWE YELL ZG

Thursday (Nov 3)

• Morning: FLWS GOLF ADT WMS AER AGIO APD ALIT AIMC ABC APG APTV ARW AAWW ATHM BALL BALY GOLD BHC BCE BKI BRKR CSII CARS LNG CQP CIM IMOS CI CCOI COMM COP CROX CMI CYBR DDOG DCPH DLX DEN DSEY DNB ESMT EPAM EXC FSS FIS FOCS FTDR ROCK GIL GOGO GTN GPRE HLMN HII H IDA INGR NSIT IBP NTLA ICE IDCC ITCI IRM IRWD ITRI ITT ISEE JCI K KTB KYMR LANC LNTH TREE LXP MAC MTSI MAR MDU MFA MGPI MRNA MODV MUR NKLA NVMI OGE OGN PCRX PZZA BTU MD PTON PENN DOC PNW PTLO PBH PWR REGN QSR RCL SPNS SRE SHAK SWI SPR SRCL STOR STRA TNK TPX TX TEVA THRY USPH UNIT VIRT VNT W WCC WLK WOW ZTS
• Afternoon:  ADPT ATGE AES AL ATSG ALKT MDRX AOSL ALTR AEE AMH COLD AMGN AMN APPN TEAM AVB BIGC BILL BL SQ BE MNRL CABO CMBM CDNA CVNA CE CHUY NET CDXS CGNX COIN COLL CODI ED CRSR CTVA CTRA CYRX CWK CUTR CYTK DH DRH BOOM DASH DOUG DEI DBX DXC LOCO NVST EOG EXAS EXPE FATE FRT FND FOXF FRG FNKO GDDY GPRO GDYN GH HRT HMN ICFI ILMN PODD IOVA KTOS LPI LGF.A LYV MTZ MAXR MAX MED MELI MTD MCHP MNTV MNST MSI MP NFG NKTR LASR NDLS LPRO OTEX OPEN OEC OUT PCTY PYPL PBA PEN PECO PLYA PRAA PGNY LUNG KWR QNST RMAX REG RGA RKT SGMO SDGR SEM SWKS SM SPT SPXC SBUX STEM STEP SYNA TMST TPIC TRUP TWLO OLED UPLD VTR VIAV VIR SPCE WBD WPM WW YELP

Friday (Nov 4)  

• Morning:  ACMR ADNT AMCX AXL AMRX ABR BEP CAH CBOE CNK DBRG D DKNG DUK ENB ESNT EVRG FLR FUBO GTES EAF HSY HUN IMGN TILE KOP LAMR MGA MBUU MOG.A PNM PPL PRLB QRTEA SYNH TU WPC

-=Vir Biotechnology (VIR) : hepatitis B drug trial results

 

Vir Biotechnology reports initial data from ongoing Phase 1 trial of VIR-3434 for chronic hepatitis B Virus infection demonstrates significant and rapid reduction in hepatitis B surface antigen

Data from the first blinded cohort of eight patients, two of whom received placebo and six of whom received a single dose of 6 mg of VIR-3434, showed that six of eight patients achieved a mean reduction of 1.3 log10 IU/mL in serum hepatitis B virus surface antigen (HBsAg) by day eight, the day when nadir was achieved in most patients.

A Phase 2 trial combining VIR-3434 with Vir's HBV-targeting siRNA, VIR-2218, is expected to commence in the second half of this year.